Eyenovia Announces Development Collaboration Agreement with Formosa Pharmaceuticals
NewsCollaboration will combine Eyenovia’s Optejet® dispensing technology with Formosa’s APNT™ nanoparticle formulation platform for the potential development of new topical therapeutics in high-value ophthalmic indications with significant…
Eyenovia Reveals Positive Evidence that Optejet® Delivery Technology Decreased Inflammation from Preserved Glaucoma Solutions Compared to Drops
NewsAcademic study found the Optejet® to be comparable to non-preserved drops in lessening the proinflammatory response
NEW YORK, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company…
Eyenovia Announces FDA Acceptance of New Drug Application for MydCombi™ for In-Office Pupil Dilation
NewsAgency assigns PDUFA action date of May 8, 2023
MydCombi™, if approved, would be the first product incorporating Eyenovia’s novel Optejet® drug delivery technology
Company also announced receipt of California Medical Device Manufacturing…
Eyenovia Announces $15 Million Credit Facility with Avenue Venture Debt Fund
NewsTransaction proceeds, together with cash on-hand, expected to fund operations through late 2023/early 2024, including potential FDA approval of MydCombi™
NEW YORK, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial…
Eyenovia announces positive results from VISION-2 Phase 3 Study of MicroLine as a potential on-demand treatment for presbyopia
News
NEW YORK, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs…
Eyenovia announces planned retirement of Lead Independent Director Ken Lee, Jr.
NewsNEW YORK, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs…
Eyenovia to Participate in Multiple Medical Meetings in September
NewsNEW YORK—September 6, 2022—Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™) therapeutics, today announced that the company will be participating…
EYENOVIA ANNOUNCES APPOINTMENT OF OPHTHALMIC INDUSTRY VETERAN MICHAEL ROWE AS CHIEF EXECUTIVE OFFICER AND BOARD MEMBER
NewsAppointment of Mr. Rowe, Eyenovia’s current Chief Operating Officer, maintains continuity while bringing significant ophthalmic industry, operations and commercialization expertise to the CEO role
NEW YORK, July 27, 2022 (GLOBE NEWSWIRE)…
EYENOVIA PROVIDES MANUFACTURING UPDATE AND ANNOUNCES APPOINTMENT OF BREN KERN AS SVP OF MANUFACTURING AND OPERATIONS
NewsNew internal manufacturing capabilities to complement existing contract manufacturing relationships
NEW YORK, July 18, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a…
EYENOVIA ANNOUNCES APPOINTMENTS OF DR. ELLEN STRAHLMAN AND DR. RAM PALANKI AS NEW AND INDEPENDENT MEMBERS OF ITS BOARD OF DIRECTORS
News
EYENOVIA ANNOUNCES APPOINTMENTS OF DR. ELLEN STRAHLMAN AND DR. RAM PALANKI AS NEW AND INDEPENDENT MEMBERS OF ITS BOARD OF DIRECTORS
NEW YORK, July 07, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), an ophthalmic pharmaceutical…
Eyenovia CEO, CMO and Chairman Dr. Sean Ianchulev to Present at Eyecelerator @ American Society of Cataract and Refractive Surgery (ASCRS) 2022
NewsEyenovia CEO, CMO and Chairman Dr. Sean Ianchulev to Present at Eyecelerator @ American Society of Cataract and Refractive Surgery (ASCRS) 2022
Presentation to review historic issues related to glaucoma therapies and how these may be addressed…
Eyenovia Announces Poster Presentation at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting
NewsApril 19, 2022 at 8:00 AM EDT
EYENOVIA ANNOUNCES POSTER PRESENTATION AT THE 2022 AMERICAN SOCIETY OF CATARACT AND REFRACTIVE SURGERY ANNUAL MEETING
Results of “SPEED” study confirm the speed of diagnostic effectiveness of a single microdose…
Eyenovia Announces Positive Study Results Demonstrating that its Optejet® Delivery Technology Reduces Conjunctival Cell Toxicity from Preserved Ophthalmic Solutions to a Level Comparable with Non-Preserved Solutions
News
Study conducted with Tufts Medical Center represents a breakthrough showing that Microdose Array Print (MAP™) technology can provide similar benefits of non-preserved medications
NEW YORK, March 15, 2022 (GLOBE NEWSWIRE) -- Eyenovia,…
Eyenovia Concludes Type A Meeting with FDA Related to MydCombi™ NDA Resubmission
NewsNo additional clinical work required; NDA resubmission anticipated in Q3 2022
NEW YORK, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose…
Eyenovia Announces Changes to the Board of Directors
NewsNEW YORK, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, today announced changes to its Board of Directors.
…
Recent Posts
- Eyenovia Announces Independent Director Stephen Benjamin To Step Down To Assume Role Of Head Of White House’s Office Of Public Engagement March 2, 2023
- Eyenovia Announces Development Collaboration Agreement with Formosa Pharmaceuticals February 15, 2023
- Eyenovia Reveals Positive Evidence that Optejet® Delivery Technology Decreased Inflammation from Preserved Glaucoma Solutions Compared to Drops January 13, 2023
Pipeline and Technology
Corporate Address
Eyenovia, Inc.
295 Madison Avenue
Suite 2400
New York, NY 10017
admin@eyenoviabio.com